Equities

Nu-Med Plus Inc

NUMD:QBB

Nu-Med Plus Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.05
  • Today's Change0.01 / 25.00%
  • Shares traded1.33k
  • 1 Year change+152.53%
  • Beta0.8534
Data delayed at least 15 minutes, as of May 31 2024 20:18 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nu-Med Plus, Inc. is a medical device company, which is principally engaged in the designing, development, enhancement and commercialization of later-stage medical devices. The Company is focused on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide (NO) delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers high purity NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery provides a range of concentrations and flow rates of NO.

  • Revenue in USD (TTM)0.00
  • Net income in USD-119.16k
  • Incorporated2011
  • Employees2.00
  • Location
    Nu-Med Plus Inc455 East 500 South, Suite #203SALT LAKE CITY 84111United StatesUSA
  • Phone+1 (801) 746-3570
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Invo Bioscience Inc4.25m-7.08m3.28m25.00------0.7709-5.68-5.682.590.00390.34739.5030.72169,953.20-57.87-94.63-128.00-151.4539.9074.91-166.64-343.110.1629-5.860.9965--267.3843.6226.24--87.09--
Venus Concept Inc73.30m-37.39m3.37m304.00------0.046-6.69-6.6913.12-3.540.74091.062.21241,125.00-37.61-32.71-56.83-44.0168.3768.16-50.77-48.501.35-3.441.40---23.2628.3114.76---35.08--
Helius Medical Technologies Inc-100.00bn-100.00bn3.57m26.00--0.6304----------2.24-----------98.37---143.57--37.27---1,580.663.26-------18.176.1437.11------
Heart Test Laboratories Inc18.60k-6.39m3.61m12.00--40.52--193.86-0.4912-0.49120.00090.13570.00260.0092.531,550.00-89.51---120.71--67.31---34,362.42--4.70-16.410.0547---64.16---31.61------
Avinger Inc7.62m-16.13m3.65m68.00------0.479-18.16-18.167.49-2.560.40841.206.38112,102.90-102.83-70.93---131.5722.4330.87-251.78-208.910.4764-10.021.38---7.51-0.673632.76---24.21--
Catheter Precision Inc439.00k-6.85m3.79m14.00--0.2044--8.63-1.03-1.030.06592.450.01150.37595.7431,357.14-17.89---19.64--94.31---1,559.68--0.8047--0.004--3,057.14---165.67------
Therapeutic Solutions International Inc98.99k-2.17m4.13m3.00--3.04--41.75-0.0007-0.00070.000030.00030.02871.134.4432,996.67-64.51-162.32-169.11--62.8567.79-2,247.41-2,391.850.0333-4.920.373---52.1395.3543.11------
Nu-Med Plus Inc0.00-119.16k4.18m2.00---------0.0014-0.00140.00-0.0020.00----0.00-350.01-447.69---------------22.74--------3.56------
SINTX Technologies Inc2.78m-8.88m4.45m43.00--0.0189--1.60-389.94-389.9474.21383.240.1381.625.8464,534.88-44.03-45.71-57.11-57.3667.9658.47-318.99-681.801.67--0.0229--68.2994.2449.75--54.10--
Vapotherm Inc70.07m-54.94m4.70m182.00------0.0671-8.62-8.6211.00-11.020.81221.467.53385,011.00-63.68-49.73-587.27-62.5445.2843.56-78.40-78.990.1259-1.272.59--2.8010.1448.62---10.38--
Nuwellis Inc8.90m-19.93m4.73m59.00--2.01--0.5317-8.30-8.302.730.13040.70761.557.04150,762.70-143.62-98.07-216.07-122.4857.4155.22-202.97-230.510.7092-4.750.00--3.7612.14-55.78--4.61--
Bioelectronics Corp1.61m-289.82k4.94m9.00------3.07-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Pressure Biosciences Inc2.27m-29.56m5.00m15.00------2.20-1.70-1.700.1299-1.221.022.289.17151,505.30-1,074.63-643.54----6.8934.75-1,050.30-798.210.0185-0.4182-----13.64-5.0521.52---34.47--
Arch Therapeutics Inc130.55k-8.43m5.02m8.00------38.47-3.68-3.680.0425-2.450.08330.0637--16,318.75-538.25-188.28---804.6333.37---6,458.14-26,945.920.0164-1.27----383.83---32.35---21.76--
Hawkeye Systems Inc0.00-804.18k5.11m44.00---------0.1186-0.11860.00-0.290.00-------66.07-330.11-----------218.49---2.7810.45------4.85------
Nexalin Technology Inc158.86k-4.94m5.21m6.00--2.24--32.77-0.6676-0.66760.02150.31290.03630.177844.0126,476.67-112.76---139.94--82.54---3,110.58--4.75--0.00---91.62---173.80------
Data as of May 31 2024. Currency figures normalised to Nu-Med Plus Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.